We are proud to be partnering with a number of laboratories around the world for the validation of virusPHIX+™ as a viral transport medium for SARS-CoV-2 testing.
A recent study from the Roslin Institute in Edinburgh, UK concluded that virusPHIX+™ inactivates SARS-CoV-2 in as little as 10 minutes when treated at a 1:1 sample to reagent ratio at room temperature. Under these conditions, a 10log6 reduction inSARS-CoV-2 virus titre was recorded:
Stabilisation of viral RNA
Another independent study by Qnostics UK demonstrated that virusPHIX+™ stabilises SARS-CoV-2 virus RNA for at least 33 days at 20ºC. Sputum samples spiked with SARS-CoV-2 RNA were analysed over 33 days, and the Ct value was compared with virusPHIX+™-treated samples and control (no stabiliser added):
Behind the scenes, Rapid Labs and RNAssist are working extensively with a number of other laboratories around the world to gather further data to support successful inactivation and stabilisation of SARS-CoV-2 for COVID-19 testing. virusPHIX™ has a significant amount of benefits over other viral transport mediums including:
- Improved Safety
virusPHIX™ does not contain guanidine, a common component found in most viral transport mediums. Guanidine can produce cyanide gas which is highly toxic when mixed with household chemicals, such as bleach, a possible risk in a home testing environment.
- Effective at ambient temperatures
We have demonstrated in the past that virusPHIX™ can effectively preserve virus RNA in samples shipped from East Africa to Paris (via Dubai!) without affecting sample quality. This robustness could have huge benefits when dealing with mass testing with a number of logistical bottlenecks affecting sample transport and analysis.
- Inactivates all other viruses and bacteria tested to date
Including Influenza A, mTb, Dengue, Zika, Vaccinia, West Nile Virus, Feline Immunodeficiency Virus (closely related to HIV) and Hepatitis B (duck).
- Compatible with most front-end RNA purification kits and optimised for automated processing in the laboratory.
If you are interested in working with us on SARS-CoV-2 validation with virusPHIX™ please contact us at email@example.com.